Recurrent Candidal Intertrigo: Challenges and Solutions

dc.authorscopusid 57197466945
dc.authorscopusid 23488373100
dc.authorscopusid 17134049200
dc.authorwosid Dilek, Nursel/Aak-5298-2021
dc.authorwosid Metin, Ahmet/Abb-7187-2020
dc.contributor.author Metin, Ahmet
dc.contributor.author Dilek, Nursel
dc.contributor.author Bilgili, Serap Gunes
dc.date.accessioned 2025-05-10T17:10:54Z
dc.date.available 2025-05-10T17:10:54Z
dc.date.issued 2018
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp [Metin, Ahmet] Yildirim Beyazit Univ, Med Sch Ankara, Dept Dermatol & Venereol, Ankara, Turkey; [Dilek, Nursel] Tayyip Erdogan Univ, Med Sch Recep, Dept Dermatol & Venereol, Rize, Turkey; [Bilgili, Serap Gunes] Yil Univ, Med Sch Yuzuncu, Dept Dermatol & Venereol, Van, Turkey en_US
dc.description.abstract Intertrigo is a common inflammatory dermatosis of opposing skin surfaces that can be caused by a variety of infectious agents, most notably candida, under the effect of mechanical and environmental factors. Symptoms such as pain and itching significantly decrease quality of life, leading to high morbidity. A multitude of predisposing factors, particularly obesity, diabetes mellitus, and immunosuppressive conditions facilitate both the occurrence and recurrence of the disease. The diagnosis of candidal intertrigo is usually based on clinical appearance. However, a range of laboratory studies from simple tests to advanced methods can be carried out to confirm the diagnosis. Such tests are especially useful in treatment-resistant or recurrent cases for establishing a differential diagnosis. The first and key step of management is identification and correction of predisposing factors. Patients should be encouraged to lose weight, followed up properly after endocrinologic treatment and intestinal colonization or peri-orificial infections should be medically managed, especially in recurrent and resistant cases. Medical treatment of candidal intertrigo usually requires topical administration of nystatin and azole group antifungals. In this context, it is also possible to use magistral remedies safely and effectively. In case of predisposing immunosuppressive conditions or generalized infections, novel systemic agents with higher potency may be required. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.2147/CCID.S127841
dc.identifier.endpage 185 en_US
dc.identifier.issn 1178-7015
dc.identifier.pmid 29713190
dc.identifier.scopus 2-s2.0-85046281017
dc.identifier.scopusquality Q2
dc.identifier.startpage 175 en_US
dc.identifier.uri https://doi.org/10.2147/CCID.S127841
dc.identifier.uri https://hdl.handle.net/20.500.14720/7581
dc.identifier.volume 11 en_US
dc.identifier.wos WOS:000430340000001
dc.identifier.wosquality Q3
dc.language.iso en en_US
dc.publisher Dove Medical Press Ltd en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Candida en_US
dc.subject Intertrigo en_US
dc.subject Recurrent Candidal Intertrigo en_US
dc.subject Candidiasis en_US
dc.subject Candidosis en_US
dc.subject Candidal Predisposals en_US
dc.title Recurrent Candidal Intertrigo: Challenges and Solutions en_US
dc.type Article en_US
dspace.entity.type Publication

Files